조용준 동구바이오 회장 “약가인하 정책, 개량신약으로 승부” [현장+]

DongkookBio's strategy to offset South Korea's August drug price reductions through innovation certification and modified drug development reflects a critical industry trend: how traditional pharma must adapt when regulatory controls limit conventional revenue models. The company's simultaneous expansion into aesthetics demonstrates the imperative to diversify into higher-margin markets while reducing reliance on price-sensitive generic drugs. This pivot signals a fundamental reshaping of competitive dynamics in increasingly price-regulated pharmaceutical markets.